Respiratory microbiota: Addressing clinical questions, informing clinical practice

Postgraduate Medical Journal

Volumn 91, Issue 1078, 2015, Pages 463-470

  Rogers, Geraint B ^a   Shaw, Dominick ^b   Marsh, Robyn L ^c   Carroll, Mary P ^d   Serisier, David J ^e,f   Bruce, Kenneth D ^g  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^e TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

^f MATER ADULT HOSPITAL   (Australia)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL VIRULENCE; BACTERIUM CONTAMINATION; BIOASSAY; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; DISEASE COURSE; DISEASE SEVERITY; DNA SEQUENCE; ENVIRONMENTAL FACTOR; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HAEMOPHILUS INFLUENZAE; HUMAN; LUNG DISEASE; METABOLOMICS; MICROBIAL COLONIZATION; MICROFLORA; PATIENT CARE; PATIENT GUIDANCE; PHYLOGENY; PHYSICAL CHEMISTRY; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; SPECIES DISTRIBUTION; TUBERCULOSIS;

EID: 84940031606     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2014-205826rep     Document Type: Review

References (40)

1. Segal LN, Rom WN, Weiden MD. Lung microbiome for clinicians. New discoveries about bugs in healthy and diseased lungs. Ann Am Thorac Soc 2014; 11: 108-16.
2. Beck JM, Young VB, Huffnagle GB. The microbiome of the lung. Transl Res 2012; 160: 258-66.
3. Rogers GB, Carroll MP, Serisier DJ, et al. Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16S ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 2004; 42: 5176-83.
4. Tunney MM, Field TR, Moriarty TF, et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008; 177: 995-1001.
5. Rogers GB, Zain NMM, Bruce KD, et al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann Am Thorac Soc 2014; 11: 496-503.
6. Sibley CD, Duan K, Fischer C, et al. Discerning the complexity of community interactions using a Drosophila model of polymicrobial infections. PLoS Pathog 2008; 4: e1000184.
7. Rogers GB, Hoffman LR, Carroll MP, et al. Interpreting infective microbiota: the importance of an ecological perspective. Trends Microbiol 2013; 21: 271-6.
8. Tunney MM, Einarsson GG, Wei L, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013; 187: 1118-26.
9. Zhao J, Murray S, Lipuma JJ. Modeling the impact of antibiotic exposure on human microbiota. Sci Rep 2014; 4: 4345.
10. Klepac-Ceraj V, Lemon KP, Martin TR, et al. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa. Environ Microbiol 2010; 12: 1293-303.
11. Di Bella JM, Bao Y, Gloor GB, et al. High throughput sequencing methods and analysis for microbiome research. J Microbiol Methods 2013; 95: 401-14.
12. Goddard AF, Staudinger BJ, Dowd SE, et al. Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota. Proc Natl Acad Sci USA 2012; 109: 13769-74.
13. Rogers GB, Skelton S, Serisier DJ, et al. Determining CF lung microbiology: a comparison of spontaneous and serially induced sputum samples using T-RFLP profiling. J Clin Microbiol 2010; 48: 78-86.
14. Willner D, Daly J, Whiley D, et al. Comparison of DNA extraction methods for microbial community profiling with an application to pediatric bronchoalveolar lavage samples. PLoS ONE 2012; 7: e34605.
15. Zhao J, Carmody LA, Kalikin LM, et al. Impact of enhanced Staphylococcus DNA extraction on microbial community measures in cystic fibrosis sputum. PLoS ONE 2012; 7: e33127.
16. Klindworth A, Pruesse E, Schweer T, et al. Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. Nucleic Acids Res 2013; 41: e1.
17. Shah N, Tang H, Doak TG, et al. Comparing bacterial communities inferred from 16S rRNA gene sequencing and shotgun metagenomics. Pac Symp Biocomput 2011: 165-76.
18. Lim YW, Evangelista JS III, Schmieder R, et al. Clinical insights from metagenomic analysis of sputum samples from patients with cystic fibrosis. J Clin Microbiol 2014; 52: 425-37.
19. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 2010; 7: 335-6.
20. Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol 2009; 75: 7537-41.
21. van der Gast CJ, Walker AW, Stressmann FA, et al. Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities. ISME J 2011; 5: 780-91.
22. Ramette A. Multivariate analyses in microbial ecology. FEMS Microbiol Ecol 2007; 62: 142-60.
23. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS ONE 2013; 8: e61217.
24. Chao A. Nonparametric estimation of the number of classes in a population. Scand J Stat 1984; 11: 265-70.
25. Chao A, Lee S. Estimating the number of classes via sample coverage. J Am Stat Assoc 1992; 87: 210-17.
26. Brower JE, Zar JH, von Ende CN. Field and laboratory methods for general ecology. Boston: McGraw-Hill, 1998.
27. Hutcheson K. A test for comparing diversities based on the Shannon formula. J Theor Biol 1970; 29: 151-4.
28. Li K, Bihan M, Yooseph S, et al. Analyses of the microbial diversity across the human microbiome. PLoS ONE 2012; 7: e32118.
29. Huang YJ, Nelson CE, Brodie EL, et al. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J Allergy Clin Immunol 2011; 127: 372-381. e1-3.
30. Huang YJ, Boushey HA. The microbiome and asthma. Ann Am Thorac Soc 2014; 11 (Suppl 1): S48-51.
31. Falkow S. Molecular Koch's postulates applied to microbial pathogenicity. Rev Infect Dis 1988; 10(Suppl 2): S274-6.
32. Conrad D, Haynes M, Salamon P, et al. Cystic fibrosis therapy: a community ecology perspective. Am J Respir Cell Mol Biol 2013; 48: 150-6.
33. Slater M, Rivett DW, Williams L, et al. The impact of azithromycin therapy on the airway microbiota in asthma. Thorax 2014; 69: 673-4.
34. Leung RK, Zhou JW, Guan W, et al. Modulation of potential respiratory pathogens by pH1N1 viral infection. Clin Microbiol Infect 2013; 19: 930-5.
35. Fierer N, Nemergut D, Knight R, et al. Changes through time: integrating microorganisms into the study of succession. Res Microbiol 2010; 161: 635-42.
36. Shade A, Peter H, Allison SD, et al. Fundamentals of microbial community resistance and resilience. Front Microbiol 2012; 3: 417.
37. Zhu B, Xiao D, Zhang H, et al. MALDI-TOF MS distinctly differentiates nontypable Haemophilus influenzae from Haemophilus haemolyticus. PLoS ONE 2013; 8: e56139.
38. Cattoir V, Narasimhan G, Skurnik D, et al. Transcriptional response of mucoid Pseudomonas aeruginosa to human respiratory mucus. MBio 2013; 3: e00410-12.
39. Wiktorowicz JE, Jamaluddin M. Proteomic analysis of the asthmatic airway. Adv Exp Med Biol 2014; 795: 221-32.
40. Kozlowska J, Rivett DW, Carroll MP, et al. The impact of Pseudomonal growth on cystic fibrosis airway secretion composition in a metabolomic investigation. Metabolomics 2013; 9: 1262-73.